Abstract
A novel candidate named 5-(3,5-dichloro-2-hydroxybenzylamino)-2- hydroxybenzoic acid (ZL006) can effectively treat focal cerebral ischemic stroke. However, the application potential of ZL006 was compromised by its poor solubility. In this study, ZL006 was loaded effectively into liposomes to improve the solubility and bioavailability. The particle size of ZL006-loaded liposomes (LPs) was about 115.5 nm with acceptable polydispersity index. The in vitro release profiles indicated that ZL006 could keep sustained release from LPs for more than 48 h. The results of pharmacokinetics study proved that the mean residence time of LPs group was 1.5-fold (P < 0.05) higher than that of free ZL006 group. Besides, the results of tissue distribution showed that the accumulation of ZL006 in brain tissue was significantly improved compared with the free ZL006 group at 1 h time after intravenous. Anti- ischemic stroke results showed that LPs could significantly enhance neuroprotection of ischemic stroke on middle cerebral artery occlusion (MCAO) rats model. In conclusion, LPs had been demonstrated to be a promising drug delivery system for ZL006 to treat ischemic stroke.
Keywords: Liposomes, pharmacodynamics pharmacokinetics, pre-formulation, stroke, tissue distribution.
Graphical Abstract
Current Signal Transduction Therapy
Title:Enhanced Neuroprotection of Ischemic Stroke Based on Liposomal Drug Delivery System Loading a Novel Uncoupler of Ischemia-induced nNOSPSD- 95
Volume: 10 Issue: 2
Author(s): Zhongyuan Wang, Lin Wu, Ming Xu, Yuan Huang, Baoyan Wang, Yue Zhao, Lingyan Lv, Yan Jiang, Qunwei Xu and Hongliang Xin
Affiliation:
Keywords: Liposomes, pharmacodynamics pharmacokinetics, pre-formulation, stroke, tissue distribution.
Abstract: A novel candidate named 5-(3,5-dichloro-2-hydroxybenzylamino)-2- hydroxybenzoic acid (ZL006) can effectively treat focal cerebral ischemic stroke. However, the application potential of ZL006 was compromised by its poor solubility. In this study, ZL006 was loaded effectively into liposomes to improve the solubility and bioavailability. The particle size of ZL006-loaded liposomes (LPs) was about 115.5 nm with acceptable polydispersity index. The in vitro release profiles indicated that ZL006 could keep sustained release from LPs for more than 48 h. The results of pharmacokinetics study proved that the mean residence time of LPs group was 1.5-fold (P < 0.05) higher than that of free ZL006 group. Besides, the results of tissue distribution showed that the accumulation of ZL006 in brain tissue was significantly improved compared with the free ZL006 group at 1 h time after intravenous. Anti- ischemic stroke results showed that LPs could significantly enhance neuroprotection of ischemic stroke on middle cerebral artery occlusion (MCAO) rats model. In conclusion, LPs had been demonstrated to be a promising drug delivery system for ZL006 to treat ischemic stroke.
Export Options
About this article
Cite this article as:
Wang Zhongyuan, Wu Lin, Xu Ming, Huang Yuan, Wang Baoyan, Zhao Yue, Lv Lingyan, Jiang Yan, Xu Qunwei and Xin Hongliang, Enhanced Neuroprotection of Ischemic Stroke Based on Liposomal Drug Delivery System Loading a Novel Uncoupler of Ischemia-induced nNOSPSD- 95, Current Signal Transduction Therapy 2015; 10 (2) . https://dx.doi.org/10.2174/1574362410666150625185717
DOI https://dx.doi.org/10.2174/1574362410666150625185717 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immune Regulation by the Posttranslational Modification O-GlcNAc
Current Signal Transduction Therapy Pharmacological Cyclin-Dependent Kinase Inhibitors (PCIs) as Potential Antiviral Drugs
Anti-Infective Agents in Medicinal Chemistry Plasma Rich in Growth Factors Enhances Wound Healing and Protects from Photo-oxidative Stress in Dermal Fibroblasts and 3D Skin Models
Current Pharmaceutical Biotechnology Beneficial and Detrimental Effects of Antioxidants Use in Sports: How is it Balanced?
Current Nutraceuticals Modulating Mitochondria-Mediated Apoptotic Cell Death through Targeting of Bcl-2 Family Proteins
Recent Patents on DNA & Gene Sequences Investigation of the pH Dependent Cytotoxicity of Paclitaxel Conjugated Gold Nanoparticles
Pharmaceutical Nanotechnology The Use of Infliximab in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Quantitative Prediction of Glucuronidation in Humans Using the In Vitro- In Vivo Extrapolation Approach
Current Topics in Medicinal Chemistry Combination of Electrochemical, Spectrometric and Other Analytical Techniques for High Throughput Screening of Pharmaceutically Active Compounds
Combinatorial Chemistry & High Throughput Screening Synthesis and Antitumor Activity of New Pyrimidine and Caffeine Derivatives
Letters in Drug Design & Discovery Synthetic Lethal Interactions in Cancer Therapy
Current Cancer Drug Targets Recent Development in Fluorescent Probes for Copper Ion Detection
Current Topics in Medicinal Chemistry Signal Enhancement Strategies for Refractive Index-Sensitive Nanobiosensor
Protein & Peptide Letters Structure-Specific Ligand Recognition of Multistranded DNA Structures
Current Topics in Medicinal Chemistry Low Dose of Anisodine Hydrobromide Induced Neuroprotective Effects in Chronic Cerebral Hypoperfusion Rats
CNS & Neurological Disorders - Drug Targets Synthesis and SARs of Coumarin Fused 1,5-Benzothiazepines as Novel Anticancer and Antioxidant Agents
Mini-Reviews in Organic Chemistry Chronic Exposure to Low-Level Cadmium in Diabetes: Role of Oxidative Stress and Comparison with Polychlorinated Biphenyls
Current Drug Targets Unfolding During Urea Denaturation of a Low Molecular Weight Phytocystatin (Thiol Protease Inhibitor) Purified from Phaseolus mungo (Urd)
Protein & Peptide Letters Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience Heparin - a Key Drug in the Treatment of the Circulatory Degenerative Diseases: Controlling its Action with Polymers
Current Pharmaceutical Design